Table of Contents    
Case Report
 
Acute pancreatitis secondary to topical and oral treatment with mesalamine in a patient with ulcerative colitis
Uribarri-Gonzalez L1, Acosta MB1, Dominguez-Muñoz JE1
1Gastroenterology Department, University Hospital of Santiago de Compostela Spain.

Article ID: 100056IJHPDLU2016
doi:10.5348/ijhpd-2016-56-CR-12

Address correspondence to:
Laura Uribarri Gonzalez
Gastroenterology, University Hospital of Santiago
Spain

Access full text article on other devices

  Access PDF of article on other devices

[HTML Full Text]   [PDF Full Text] [Print This Article]
[Similar article in Pumed] [Similar article in Google Scholar]

How to cite this article:
Uribarri-Gonzalez L, Barreiro-de Acosta M, Dominguez-Muñoz JE. Acute pancreatitis secondary to topical and oral treatment with mesalamine in a patient with ulcerative colitis. Int J Hepatobiliary Pancreat Dis 2016;6:64–67.


Abstract
Introduction: Derivatives of 5-aminosalicylic acid (5-ASA) as Claversal® used for the treatment of inflammatory bowel disease may induce acute pancreatitis both orally as topically. Mesalazine is the only treatment used in our environment within the compounds of 5-ASA, due to other molecules not being available. It is available for both oral and topical, being topical form highly relevant considering that its compounds are rapidly absorbed once acetylated, resulting in inactive metabolites. Nowadays the mechanism or pathway by which it is produced is not really clear, neither the relationship with the intervals between exposure of treatment nor the onset of clinical symptoms, due to some cases in which there was no relationship with the duration, which was our case.
Case Report: We report one case of 5-ASA induced pancreatitis. A 35-year-old male whose first episode was secondary to oral form with subsequent recurrence after beginning with topical form.
Conclusion: We would like to point out that after an episode of pancreatitis due to oral mesalamine, topical mesalamine should not be prescribed.

Keywords: Mesalamine, inflammatory bowel disease, pancreatitis, topical treatment


[HTML Full Text]   [PDF Full Text]

Author Contributions
Laura Uribarri-Gonzalez – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Manuel Barreiro-de Acosta – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
J. Enrique Dominguez-Muñoz – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Guarantor of submission
The corresponding author is the guarantor of submission.
Source of support
None
Conflict of interest
Authors declare no conflict of interest.
Copyright
© 2016 Laura Uribarri Gonzalez et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.